

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH AN PERIPHERAL ARTERY DISEASE

1. Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S *et al*: **2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS).** *European heart journal* 2018, **39**(9):763-816.
2. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FGR, Hamburg NM, Kinlay S *et al*: **2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary.** *Vascular medicine (London, England)* 2017, **22**(3):Np1-np43.
3. Hussain MA, Al-Omran M, Creager MA, Anand SS, Verma S, Bhatt DL: **Antithrombotic Therapy for Peripheral Artery Disease: Recent Advances.** *J Am Coll Cardiol* 2018, **71**(21):2450-2467.
4. Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS *et al*: **Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.** *The New England journal of medicine* 2017, **376**(1):32-40.
5. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS *et al*: **Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.** *The New England journal of medicine* 2017, **377**(14):1319-1330.
6. Niessner A, Agewall S: **Critical appraisal of the COMPASS trial.** *European Heart Journal - Cardiovascular Pharmacotherapy* 2018, **4**(4):191-192.
7. Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme P, Avezum A, Fox KAA, Berkowitz SD, Bangdiwala SI *et al*: **Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.** *JAMA Cardiol* 2021, **6**(1):21-29.
8. National Institute for Health and Care Excellence: **Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease [NICE Guidance TA607].** 2019.
9. Mureebe L: **Peripheral arterial disease.** In: *BMJ Best Practice.* 2020.
10. Brass EP, Hiatt WR: **Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease.** 2017, **136**(9):785-786.
11. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR: **Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.** *Jama* 2009, **301**(18):1909-1919.
12. CAPRIE Steering Committee: **A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).** *Lancet (London, England)* 1996, **348**(9038):1329-1339.

13. Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G: **Cilostazol for intermittent claudication**. *The Cochrane database of systematic reviews* 2014(10):Cd003748.
14. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K *et al*: **Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial**. *Lancet (London, England)* 2018, **391**(10117):219-229.
15. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P *et al*: **Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke**. *The New England journal of medicine* 2008, **359**(12):1238-1251.
16. Bell AD, Roussin A, Cartier R, Chan WS, Douketis JD, Gupta A, Kraw ME, Lindsay TF, Love MP, Pannu N *et al*: **The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines**. *Canadian Journal of Cardiology* 2011, **27**(3):S1-S59.
17. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, Golzarian J, Gornik HL, Halperin JL, Jaff MR *et al*: **2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines**. *Circulation* 2011, **124**(18):2020-2045.
18. National Institute for Health and Care Excellence: **Lower limb peripheral arterial disease: diagnosis and management** [NICE Guideline CG147]. 2012.
19. Firnhaber JM, Powell CS: **Lower Extremity Peripheral Artery Disease: Diagnosis and Treatment**. *Am Fam Physician* 2019, **99**(6):362-369.
20. Hackam DG, Duong-Hua ML, Mamdani M, Li P, Tobe SW, Spence JD, Garg AX: **Angiotensin inhibition in renovascular disease: a population-based cohort study**. *American heart journal* 2008, **156**(3):549-555.
21. Chrysochou C, Foley RN, Young JF, Khavandi K, Cheung CM, Kalra PA: **Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease**. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association* 2012, **27**(4):1403-1409.
22. Losito A, Errico R, Santirosi P, Lupattelli T, Scalera GB, Lupattelli L: **Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition**. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association* 2005, **20**(8):1604-1609.
23. Cianci R, Martina P, Borghesi F, di Donato D, Polidori L, Lai S, Ascoli G, de Francesco I, Zaccaria A, Gigante A *et al*: **Revascularization versus medical therapy for renal artery stenosis: antihypertensive drugs and renal outcome**. *Angiology* 2011, **62**(1):92-99.
24. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD: **Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial**. *Jama* 2010, **303**(9):841-848.
27. Bedenis R, Lethaby A, Maxwell H, Acosta S, Prins MH: **Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery**. *The Cochrane database of systematic reviews* 2015(2):Cd000535.
28. Evans KL, Tuttle KR, Folt DA, Dawson T, Haller ST, Brewster PS, He W, Jamerson K, Dworkin LD, Cutlip DE *et al*: **Use of renin-angiotensin inhibitors in people with renal**

- artery stenosis.** *Clinical journal of the American Society of Nephrology : CJASN* 2014, **9**(7):1199-1206.
29. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J *et al*: **The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.** *BMJ (Clinical research ed)* 2008, **337**:a1840.
 30. Diehm C, Allenberg JR, Pittrow D, Mahn M, Tepohl G, Haberl RL, Darius H, Burghaus I, Trampisch HJ: **Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease.** *Circulation* 2009, **120**(21):2053-2061.
 31. Catalano M, Born G, Peto R: **Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial.** *Journal of internal medicine* 2007, **261**(3):276-284.
 32. Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G *et al*: **Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis.** *Jama* 2008, **300**(2):197-208.
 33. Abbott JD, van Zuuren EJ, Oettgen P: **Peripheral arterial disease (PAD) of lower extremities.** *DynaMed* 2018.
 34. Darmon A, Bhatt DL, Elbez Y, Aboyans V, Anand S, Bosch J, Branch KR, Connolly SJ, Dyal L, Eikelboom JW *et al*: **External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.** *European heart journal* 2018, **39**(9):750-757a.
 35. Chen C, Kan Y, Shi Z, Guo D, Fu W, Li Y, Lv Q, Li X, Si Y: **Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis.** *Front Pharmacol* 2020, **11**:608247.
 36. Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N *et al*: **Rivaroxaban in Peripheral Artery Disease after Revascularization.** *The New England journal of medicine* 2020, **382**(21):1994-2004.
 37. Antithrombotic Trialists' Collaboration: **Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.** *BMJ (Clinical research ed)* 2002, **324**(7329):71-86.
 38. Hess CN, Hiatt WR: **Antithrombotic Therapy for Peripheral Artery Disease in 2018.** *Jama* 2018, **319**(22):2329-2330.
 39. Pickett CA, Jackson JL, Hemann BA, Atwood JE: **Carotid bruits as a prognostic indicator of cardiovascular death and myocardial infarction: a meta-analysis.** *Lancet (London, England)* 2008, **371**(9624):1587-1594.
 40. National Institute for Health and Care Excellence. **Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events** [Technology appraisal guidance 210]. 2010. nice.org.uk/guidance/ta210.
 41. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C *et al*: **2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).** *European heart journal* 2016, **37**(29):2315-2381.

42. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC: **Lipid-lowering for peripheral arterial disease of the lower limb.** *The Cochrane database of systematic reviews* 2007(4):Cd000123.
43. Antoniou GA, Fisher RK, Georgiadis GS, Antoniou SA, Torella F: **Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis.** *Vascular pharmacology* 2014, **63**(2):79-87.
44. Heart Protection Study Collaborative Group: **Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions.** *Journal of vascular surgery* 2007, **45**(4):645-654; discussion 653-644.
45. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Jr., Goto S, Ohman EM, Elbez Y, Sritara P, Baumgartner I *et al*: **Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry.** *European heart journal* 2014, **35**(41):2864-2872.
46. Westin GG, Armstrong EJ, Bang H, Yeo KK, Anderson D, Dawson DL, Pevec WC, Amsterdam EA, Laird JR: **Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia.** *J Am Coll Cardiol* 2014, **63**(7):682-690.
47. Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, Reist C, Im K, Bohula EA, Isaza D *et al*: **Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.** *J Am Coll Cardiol* 2016, **67**(4):353-361.
48. Meade T, Zuhrie R, Cook C, Cooper J: **Bezafibrate in men with lower extremity arterial disease: randomised controlled trial.** *BMJ (Clinical research ed)* 2002, **325**(7373):1139.
49. Ramos R, Garcia-Gil M, Comas-Cufi M, Quesada M, Marrugat J, Elosua R, Sala J, Grau M, Marti R, Ponjoan A *et al*: **Statins for Prevention of Cardiovascular Events in a Low-Risk Population With Low Ankle Brachial Index.** *J Am Coll Cardiol* 2016, **67**(6):630-640.
50. Vogel TR, Dombrovskiy VY, Galinanes EL, Kruse RL: **Preoperative statins and limb salvage after lower extremity revascularization in the Medicare population.** *Circulation Cardiovascular interventions* 2013, **6**(6):694-700.
51. Mohler ER, 3rd, Hiatt WR, Creager MA: **Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.** *Circulation* 2003, **108**(12):1481-1486.
52. Kithcart AP, Beckman JA: **ACC/AHA Versus ESC Guidelines for Diagnosis and Management of Peripheral Artery Disease: JACC Guideline Comparison.** *J Am Coll Cardiol* 2018, **72**(22):2789-2801.
53. Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS: **Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies.** *European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery* 2009, **38**(4):463-474.
54. Dawson DL, Cutler BS, Hiatt WR, Hobson RW, 2nd, Martin JD, Bortey EB, Forbes WP, Strandness DE, Jr.: **A comparison of cilostazol and pentoxifylline for treating intermittent claudication.** *The American journal of medicine* 2000, **109**(7):523-530.
55. Salhiyyah K, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA: **Pentoxifylline for intermittent claudication.** *Cochrane Database of Systematic Reviews* 2012(1).

56. Bagger JP, Helligsoe P, Randsbaek F, Kimose HH, Jensen BS: **Effect of Verapamil in Intermittent Claudication**. 1997, **95**(2):411-414.
57. Gargiulo G, Giugliano G, Brevetti L, Sannino A, Schiattarella GG, Serino F, Carbone A, Scudiero F, Ferrone M, Corrado R *et al*: **Use of statins in lower extremity artery disease: a review**. *BMC surgery* 2012, **12** Suppl 1:S15.
58. McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, Taylor L, Chan C, Sharma L, Schneider JR *et al*: **Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease**. *Circulation* 2003, **107**(5):757-761.
59. Robertson L, Andras A: **Prostanoids for intermittent claudication**. *The Cochrane database of systematic reviews* 2013(4):Cd000986.
60. Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby G: **Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication**. *The British journal of surgery* 2012, **99**(12):1630-1638.
62. Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G: **Antiplatelet agents for intermittent claudication**. *The Cochrane database of systematic reviews* 2011(11):CD001272.
63. Bevan GH, White Solaru KT: **Evidence-Based Medical Management of Peripheral Artery Disease**. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2020, **40**:541-553.
64. Corrado E, Mignano A, Coppola G: **Use of statins in patients with peripheral artery disease**. *Trends Cardiovasc Med* 2020, **30**(5):257-262.
65. Investigators TWAVET: **Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease**. *New England Journal of Medicine* 2007, **357**(3):217-227.
66. Pharmascience Inc.: **ASA (Acetylsalicylic Acid Delayed-release Tablets)**. In: *CA Product Monograph*. Montreal, QC; 2021.
67. Kem Pharma: **Aspir-81 (Acetylsalicylic Acid)**. In: *US Product Monograph*. Setauket, NY; 2020.
68. **Adult Drug Book** In.: University of Louisville, Division of Nephrology, Kidney Disease Program; 2021.
69. Slate Run Pharmaceuticals LLC: **Cilostazol**. In: *US Product Monograph*. Columbus, OH; 2020.
70. sanofi-aventis Canada Inc.: **Plavix (clopidogrel)**. In: *CA Product Monograph*. Laval, QC; 2020.
71. Sun Pharmaceutical Industries Inc.: **Clopidogrel bisulfate**. In: *US Product Monograph*. Cranbury, NJ; 2021.
72. Bayer Inc.: **Xarelto (rivaroxaban)**. In: *CA Product Monograph*. Mississauga, ON; 2019.
73. Janssen Pharmaceuticals Inc.: **Xarelto (rivaroxaban)**. In: *US Product Monograph*. Titusville, NJ; 2020.
74. AstraZeneca Canada Inc.: **Brilinta (ticagrelor)**. In: *CA Product Monograph*. Mississauga, ON; 2019.
75. AstraZeneca Pharmaceuticals LP: **Brilinta (ticagrelor)**. In: *US Product Monograph*. Wilmington, DE; 2021.
76. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ *et al*: **Pharmacogenetics: from bench to byte--an update of guidelines**. *Clin Pharmacol Ther* 2011, **89**(5):662-673.
77. **Dutch Guidelines**. [<https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf>]
78. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR *et al*: **Clinical Pharmacogenetics Implementation**

- Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.** *Clin Pharmacol Ther* 2013, **94**(3):317-323.
79. Chung JY, Cho JY, Yu KS, Kim JR, Jung HR, Lim KS, Jang IJ, Shin SG: **Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers.** *Clin Pharmacol Ther* 2005, **77**(6):486-494.
 80. Mastalerz L, Setkowicz M, Sanak M, Rybarczyk H, Szczeklik A: **Familial aggregation of aspirin-induced urticaria and leukotriene C synthase allelic variant.** *The British journal of dermatology* 2006, **154**(2):256-260.
 81. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A: **Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma.** *The Journal of allergy and clinical immunology* 2004, **113**(4):771-775.
 82. Lee HY, Lee JW, Lee KW, Park MH, Park HS: **The HLA allele marker for differentiating ASA hypersensitivity phenotypes.** *Allergy* 2009, **64**(9):1385-1387.
 83. Choi JH, Lee KW, Oh HB, Lee KJ, Suh YJ, Park CS, Park HS: **HLA association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population.** *The Journal of allergy and clinical immunology* 2004, **113**(3):562-564.
 84. Dekker JW, Nizankowska E, Schmitz-Schumann M, Pile K, Bochenek G, Dyczek A, Cookson WO, Szczeklik A: **Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes.** *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 1997, **27**(5):574-577.
 85. Matsubara Y, Murata M, Watanabe G, Ikeda Y: **Enhancing effect of the (145)Met-allele of GPIb alpha on platelet sensitivity to aspirin under high-shear conditions.** *Thrombosis research* 2008, **123**(2):331-335.
 86. Fujiwara T, Ikeda M, Esumi K, Fujita TD, Kono M, Tokushige H, Hatoyama T, Maeda T, Asai T, Ogawa T *et al*: **Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity.** *The pharmacogenomics journal* 2007, **7**(6):395-403.
 87. Lepantalo A, Mikkelsson J, Resendiz JC, Viiri L, Backman JT, Kankuri E, Karhunen PJ, Lassila R: **Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients.** *Thrombosis and haemostasis* 2006, **95**(2):253-259.
 88. Verschuren JJ, Boden H, Wessels JA, van der Hoeven BL, Trompet S, Heijmans BT, Putter H, Guchelaar HJ, Schalij MJ, Jukema JW: **Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.** *International journal of cardiology* 2013, **167**(6):2882-2888.
 89. Goodman T, Ferro A, Sharma P: **Pharmacogenetics of aspirin resistance: a comprehensive systematic review.** *Br J Clin Pharmacol* 2008, **66**(2):222-232.
 90. Ulehlova J, Slavik L, Kucerovala J, Krcova V, Vaclavik J, Indrak K: **Genetic polymorphisms of platelet receptors in patients with acute myocardial infarction and resistance to antiplatelet therapy.** *Genet Test Mol Biomarkers* 2014, **18**(9):599-604.
 91. Martin J, Williams AK, Klein MD, Sriramoju VB, Madan S, Rossi JS, Clarke M, Cicci JD, Cavallari LH, Weck KE *et al*: **Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting.** *Genet Med* 2019.
 92. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF: **Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis.** *The pharmacogenomics journal* 2011, **11**(3):199-206.

93. Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, Wei W: **Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.** *Arch Cardiovasc Dis* 2013, **106**(10):517-527.
94. Kheiri B, Osman M, Abdalla A, Haykal T, Pandrangi PV, Chahine A, Ahmed S, Osman K, Bachuwa G, Hassan M *et al*: **CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.** *Catheter Cardiovasc Interv* 2019, **93**(7):1246-1252.
95. Williams AK, Klein MD, Martin J, Weck KE, Rossi JS, Stouffer GA, Lee CR: **CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention.** *Circ Genom Precis Med* 2019, **12**(2):e002441.
96. Cavallari LH, Lee CR, Beitelshes AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV *et al*: **Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.** *JACC Cardiovasc Interv* 2018, **11**(2):181-191.
97. Bergmeijer TO, Reny JL, Pakyz RE, Gong L, Lewis JP, Kim EY, Aradi D, Fernandez-Cadenas I, Horenstein RB, Lee MTM *et al*: **Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).** *American heart journal* 2018, **198**:152-159.
98. Danielak D, Karazniewicz-Lada M, Komosa A, Burchardt P, Lesiak M, Kruszyna L, Graczyk-Szuster A, Glowka F: **Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.** *Eur J Clin Pharmacol* 2017, **73**(12):1623-1632.
99. Hou X, Shi J, Sun H: **Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis.** *Eur J Clin Pharmacol* 2014, **70**(9):1041-1047.
100. Rodriguez-Gonzalez F, Martinez-Quintana E, Saavedra P, Medina-Gil JM, Riano M, Garay-Sanchez P, Tugores A: **CYP2C19 or CYP3A5 Genotyping Does Not Predict Clinical Response to Clopidogrel.** *J Clin Pharmacol* 2018, **58**(10):1274-1283.
101. Wu Y, Zhou Y, Pan Y, Zhao X, Liu L, Wang D, Wang C, Li H, Johnston SC, Meng X *et al*: **Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.** *The pharmacogenomics journal* 2018, **18**(6):713-720.
102. Tatarunas V, Kupstyte N, Giedraitiene A, Skipskis V, Jakstas V, Zvikas V, Lesauskaite V: **The impact of CYP2C19*2, CYP4F2*3, and clinical factors on platelet aggregation, CYP4F2 enzyme activity, and 20-hydroxyeicosatetraenoic acid concentration in patients treated with dual antiplatelet therapy.** *Blood Coagul Fibrinolysis* 2017, **28**(8):658-664.
103. Oledzki S, Kornacewicz-Jach Z, Safranow K, Kiedrowicz R, Gawronska-Szklarz B, Jastrzebska M, Goracy J: **Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.** *Eur J Clin Pharmacol* 2017, **73**(9):1085-1094.
104. Collet JP, Hulot JS, Cuisset T, Range G, Cayla G, Van Belle E, Elhadad S, Rousseau H, Sabouret P, O'Connor SA *et al*: **Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study.** *Eur J Clin Pharmacol* 2015, **71**(11):1315-1324.
105. Sorich MJ, Rowland A, McKinnon RA, Wiese MD: **CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary**

- intervention and in Asian populations treated with clopidogrel: a meta-analysis.** *Circulation Cardiovascular genetics* 2014, **7**(6):895-902.
106. Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, Li X, Huang L, Johnston SC, Zhao X *et al*: **Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.** *Circulation* 2017, **135**(1):21-33.
 107. Lewis JP, Horenstein RB, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, Tanner K, Chai S, Bliden KP, Tantry US *et al*: **The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.** *Pharmacogenetics and genomics* 2013, **23**(1):1-8.
 108. Tarkiainen EK, Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M: **Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans.** *Clin Pharmacol Ther* 2015, **97**(6):650-658.
 109. Diaz-Villamarin X, Davila-Fajardo CL, Martinez-Gonzalez LJ, Carmona-Saez P, Sanchez-Ramos J, Alvarez Cubero MJ, Salmeron-Febres LM, Cabeza Barrera J, Fernandez-Quesada F: **Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty.** *Pharmacogenomics* 2016, **17**(12):1327-1338.
 110. Leunissen TC, Peeters Weem SM, Urbanus RT, den Ruijter HM, Moll FL, Asselbergs FW, de Borst GJ: **High On-Treatment Platelet Reactivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Values.** *European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery* 2016, **52**(2):198-204.
 111. Guo B, Tan Q, Guo D, Shi Z, Zhang C, Guo W: **Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.** *Journal of vascular surgery* 2014, **60**(4):993-1001.
 112. Prins MH, Lensing AWA, Prandoni P, Wells PS, Verhamme P, Beyer-Westendorf J, Bauersachs R, Bounameaux H, Brighton TA, Cohen AT *et al*: **Risk of recurrent venous thromboembolism according to baseline risk factor profiles.** *Blood Adv* 2018, **2**(7):788-796.
 113. Zhong Z, Hou J, Zhang Q, Li B, Li C, Liu Z, Yang M, Zhong W, He X, Wu H *et al*: **Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.** *Eur J Clin Pharmacol* 2018, **74**(4):423-431.
 114. Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K, Gurbel PA: **First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.** *Circulation Cardiovascular genetics* 2010, **3**(6):556-566.
 115. Kim HS, Lim Y, Oh M, Ghim JL, Kim EY, Kim DH, Shin JG: **The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.** *Br J Clin Pharmacol* 2016, **81**(2):301-312.